Shreeyashi Ojha | BioProcess International

Shreeyashi Ojha

Reporter, BioProcess Insider

Journalist covering the manufacturing and processing sectors for biopharmaceuticals globally.

Originally from India, I am a Londoner at heart. I have recently graduated from Goldsmiths, University of London.

Feel free to reach out to me at: [email protected].

Latest from Shreeyashi Ojha

Facilities & Capacity

Sartorius, McMaster open Canadian bioprocessing hub Sartorius, McMaster open Canadian bioprocessing hub

byShreeyashi Ojha

Jan 23, 2025

2 Min Read

Therapeutic Class

A Gen Z guide to bioprocessing trends of '25 A Gen Z guide to bioprocessing trends of '25

byShreeyashi Ojha

Jan 22, 2025

3 Min Read

All from Shreeyashi Ojha

Iconovo taps Lonza for spray-dried obesity biologic

Iconovo taps Lonza for spray-dried obesity biologic

byShreeyashi Ojha, Reporter

Therapeutic Class

Thermo cites Catalent, capacity, and Trumpian tariffs in positive CDMO outlook

Thermo cites Catalent, capacity, and Trumpian tariffs in positive CDMO outlook

byShreeyashi Ojha, Reporter

Samsung Bio lands $1.4bn contract with undisclosed EU client

Samsung Bio lands $1.4bn contract with undisclosed EU client

byShreeyashi Ojha, Reporter

Facilities & Capacity

Lilly expands India footprint with Hyderabad plant

Lilly expands India footprint with Hyderabad plant

byShreeyashi Ojha, Reporter

Boehringer bolsters ADC biz with $1.3bn Synaffix deal

Boehringer bolsters ADC biz with $1.3bn Synaffix deal

byShreeyashi Ojha, Reporter

Facilities & Capacity

Insider’s wrapped: BIOSECURE, AI, CDMO shakeups shaped 2024

Insider’s wrapped: BIOSECURE, AI, CDMO shakeups shaped 2024

byShreeyashi Ojha, Reporter

SK pharmteco secures $1.4bn GLP-1 deal

SK pharmteco secures $1.4bn GLP-1 deal

byShreeyashi Ojha, Reporter

Novo Catalent deal clears regulatory hurdles

Novo Catalent deal clears regulatory hurdles

byShreeyashi Ojha, Reporter

Asahi strengthens autoimmune focus with Chiome partnership

Asahi strengthens autoimmune focus with Chiome partnership

byShreeyashi Ojha, Reporter

Facilities & Capacity

Ins & Outs: Resilience, AGC, Sartorius ride the CEO carousel

Ins & Outs: Resilience, AGC, Sartorius ride the CEO carousel

byShreeyashi Ojha, Reporter

Facilities & Capacity

Diabetes drug firms Sanofi, Novo expand global footprint

Diabetes drug firms Sanofi, Novo expand global footprint

byShreeyashi Ojha, Reporter

Facilities & Capacity

BioMarin bolsters Ireland footprint with $63m expansion

BioMarin bolsters Ireland footprint with $63m expansion

byShreeyashi Ojha, Reporter

Therapeutic Class

Is India reliable? Addressing challenges in the pharma industry

Is India reliable? Addressing challenges in the pharma industry

byShreeyashi Ojha, Reporter

Facilities & Capacity

Novo expands EU footprint with $200m Novavax plant

Novo expands EU footprint with $200m Novavax plant

byShreeyashi Ojha, Reporter

Therapeutic Class

India’s pharma future relies on regulatory strength

India’s pharma future relies on regulatory strength

byShreeyashi Ojha, Reporter

Facilities & Capacity

Sanofi opens AI-powered $595m facility in Singapore

Sanofi opens AI-powered $595m facility in Singapore

byShreeyashi Ojha, Reporter

Facilities & Capacity

Lonza doubles bioconjugation capacity at Swiss facility

Lonza doubles bioconjugation capacity at Swiss facility

byShreeyashi Ojha, Reporter

Facilities & Capacity

Cytiva strengthens APAC presence with Korea plant

Cytiva strengthens APAC presence with Korea plant

byShreeyashi Ojha, Reporter

Therapeutic Class

Repligen credits 10% revenue surge to new modalities and M&As

Repligen credits 10% revenue surge to new modalities and M&As

byShreeyashi Ojha, Reporter

Novo taps Ascendis in $285m GLP-1 deal

Novo taps Ascendis in $285m GLP-1 deal

byShreeyashi Ojha, Reporter

Facilities & Capacity

AmplifyBio bolsters Ohio plant with $50m backing from Vitrian

AmplifyBio bolsters Ohio plant with $50m backing from Vitrian

byShreeyashi Ojha, Reporter

Therapeutic Class

Post-pandemic dip: Panelists discuss CGT challenges

Post-pandemic dip: Panelists discuss CGT challenges

byShreeyashi Ojha, Reporter

Facilities & Capacity

Thermo Fisher expands India footprint with bioprocess design center

Thermo Fisher expands India footprint with bioprocess design center

byShreeyashi Ojha, Reporter

Facilities & Capacity

Sterling doubles ADC capacity at UK facility

Sterling doubles ADC capacity at UK facility

byShreeyashi Ojha, Reporter

Facilities & Capacity

Ardena bolsters bioanalytical capacity with Netherlands lab construction

Ardena bolsters bioanalytical capacity with Netherlands lab construction

byShreeyashi Ojha, Reporter

Pluri, BIRAD bring tumor-fighting MAIT cells to commercial viability

Pluri, BIRAD bring tumor-fighting MAIT cells to commercial viability

byShreeyashi Ojha, Reporter

Facilities & Capacity

MilliporeSigma bolsters ADC business with $76m US expansion

MilliporeSigma bolsters ADC business with $76m US expansion

byShreeyashi Ojha, Reporter

Facilities & Capacity

Celltechna opens $54m gene therapy center in Lithuania

Celltechna opens $54m gene therapy center in Lithuania

byShreeyashi Ojha, Reporter

Facilities & Capacity

Rentschler bolsters production with 3,400 square-meter expansion

Rentschler bolsters production with 3,400 square-meter expansion

byShreeyashi Ojha, Reporter

Facilities & Capacity

Ins & Outs: Forge, Veranova, Cellipont announce C-suite rejigs

Ins & Outs: Forge, Veranova, Cellipont announce C-suite rejigs

byShreeyashi Ojha, Reporter

Therapeutic Class

Investors prioritize efficacy in the CGT biz, experts say

Investors prioritize efficacy in the CGT biz, experts say

byShreeyashi Ojha, Reporter

Facilities & Capacity

CDMO AGC places CO plant on ice amid turbulent CGT economy

CDMO AGC places CO plant on ice amid turbulent CGT economy

byShreeyashi Ojha, Reporter

Therapeutic Class

USPs and efficacy driving CGT competitiveness

USPs and efficacy driving CGT competitiveness

byShreeyashi Ojha, Reporter

Subscribe to receive our monthly print or digital publication

Join our 70,000+ readers. And yes, it's completely free.